Open AccessLeft ventricular hypertrophy and renin-angiotensin-aldosterone system: AT1-receptor blockers are in the focus
Author(s) -
А. В. Барсуков,
D V Glukhovskoy,
М С Таланцева,
З. В. Багаева,
Елена Николаевна Пронина,
М. П. Зобнина,
Т. С. Свеклина,
А. Е. Коровин
Publication year - 2013
Publication title -
sistemnye gipertenzii
Language(s) - English
Resource type - Journals
eISSN - 2542-2189
pISSN - 2075-082X
DOI - 10.26442/sg28961
Subject(s) - left ventricular hypertrophy , medicine , cardiology , ventricle , telmisartan , renin–angiotensin system , muscle hypertrophy , angiotensin ii receptor type 1 , aldosterone , essential hypertension , blood pressure
Left ventricular hypertrophy (LVH) is one of the cardio-vascular continuum components, determining the prognosis of patient with essential hypertension (EH). Pathogenesis of LVH has a multifactor character. Important role in development of cardiomyocites hypertrophy, Intracardiac fibrosis, left ventricle cavity dilation belongs to renin-angiotensin-aldosteron system (RAAS). Pharmacologic blockade of RAAS composes the basis of therapy, directed to LVH regress. Application of Telmisartan is considered high-reasonable approach to treatment of EH-patient with LVH.